<bill session="117" type="s" number="5123" updated="2023-09-01T18:30:31Z">
  <state datetime="2022-11-17">REFERRED</state>
  <status>
    <introduced datetime="2022-11-17"/>
  </status>
  <introduced datetime="2022-11-17"/>
  <titles>
    <title type="display">Breakthrough Therapies Act</title>
    <title type="short" as="introduced">Breakthrough Therapies Act</title>
    <title type="official" as="introduced">A bill to amend the Controlled Substances Act to modify the registration requirements relating to research, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="B001288"/>
  <cosponsors>
    <cosponsor bioguide_id="P000603" joined="2022-11-17"/>
  </cosponsors>
  <actions>
    <action datetime="2022-11-17">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-11-17" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSJU" name="Senate Judiciary" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Crime and law enforcement"/>
  </subjects>
  <amendments/>
  <summary date="2023-09-01T18:18:06Z" status="Introduced in Senate">Breakthrough Therapies Act

This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.</summary>
</bill>
